Ceruloplasmin and the Extent of Heart Failure in Ischemic and Nonischemic Cardiomyopathy Patients
Figure 2
Ceruloplasmin levels in NYHA II, NYHA III, and NYHA IV subgroups. There was no significant difference among different NYHA subgroups in ischemic cardiomyopathy patients . In nonischemic cardiomyopathy patients, the CP levels showed statistical difference among NYHA II, NYHA III, and NYHA IV subgroups .
